Maxim Group analyst Jason McCarthy maintained a Buy rating on OncoSec Medical (NASDAQ: ONCS) today and set a price target of $5. The company’s shares closed on Friday at $1.62.
McCarthy said:
“While CAR-T took a “breather” in our view at ASCO this year, the cytokine and checkpoint space was active. OncoSec provided an update on the design of the ongoing P2b study with Merck (MRK – NR) evaluating the combination of DNA-based IL-12 + Keytruda in late stage melanoma patients.”
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 12.6% and a 45.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
OncoSec Medical has an analyst consensus of Moderate Buy, with a price target consensus of $4.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.95 and a one-year low of $0.88. Currently, OncoSec Medical has an average volume of 1.18M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OncoSec Medical, Inc. engages in the design and commercialize medical products for the treatment of cancer. It involves in the discovery and development of novel immunotherapeutic products to improve treatment options for patients and physicians, which intends to treat oncology indications.
